Artemeter
| Evidensnivå: L5 | Förutsagda indikationer: 0 st |
Innehållsförteckning
Artemether: Antimalarial Drug — Awaiting Repurposing Prediction
One-Sentence Summary
Artemether (ARTEMETER) is a well-known artemisinin derivative primarily used for the treatment of malaria, particularly Plasmodium falciparum infections. Currently, the TxGNN model has no predicted new indications for this drug, and no clinical trial or literature evidence has been compiled in this evidence pack. Further data collection is required before a repurposing evaluation can proceed.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Malaria (artemisinin-based antimalarial) |
| Predicted New Indication | — (No TxGNN prediction available) |
| TxGNN Prediction Score | — |
| Evidence Level | L5 (No studies available in this pack) |
| Taiwan Market Status | ✗ Not marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, there is no TxGNN-predicted indication for Artemether in this evidence pack, so a mechanistic plausibility analysis cannot be conducted at this time.
For context, Artemether is a methyl ether derivative of artemisinin, a sesquiterpene lactone isolated from the plant Artemisia annua. It exerts its antimalarial activity primarily through the generation of free radicals upon interaction with heme iron in the parasite's food vacuole, leading to alkylation of parasite proteins and damage to parasite membranes. It is commonly administered in combination with lumefantrine (marketed internationally as Coartem®/Riamet®) as an artemisinin-based combination therapy (ACT).
Detailed mechanism of action data was not available in the evidence pack (flagged as Data Gap DG002). Once MOA data is retrieved from DrugBank and a TxGNN prediction is generated, a proper mechanistic plausibility assessment can be performed. Notably, artemisinin derivatives have attracted research interest beyond malaria — including potential anticancer, anti-inflammatory, and antiviral properties — which may inform future repurposing predictions.
Clinical Trial Evidence
Currently no related clinical trials are registered in this evidence pack.
No predicted indication has been generated by TxGNN, so no indication-specific clinical trial search was performed.
Literature Evidence
Currently no related literature is available in this evidence pack.
No predicted indication has been generated by TxGNN, so no indication-specific literature search was performed.
Taiwan Market Information
Artemether is not currently marketed in Taiwan. No TFDA drug licenses were found.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| — | — | — | No licenses on record |
Safety Considerations
Please refer to the package insert for safety information. No TFDA package insert warnings, contraindications, or drug interaction data were available in this evidence pack.
Data Gaps Identified:
- DG001 (Blocking): TFDA package insert warnings and contraindications have not been retrieved. This blocks entry into the S1 safety preliminary assessment. Remediation: Download and parse the package insert PDF from the TFDA website.
- DG002 (High): Mechanism of action (MOA) data is missing, impacting mechanistic relevance analysis. Remediation: Query the DrugBank API.
Conclusion and Next Steps
Decision: Hold
Rationale: No TxGNN-predicted indication exists for Artemether at this time, and the drug is not marketed in Taiwan (0 licenses). Multiple critical data gaps — including MOA and safety information — must be resolved before any repurposing evaluation can begin.
To proceed, the following is needed:
- Generate TxGNN repurposing predictions for Artemether by ensuring the drug is properly mapped in the knowledge graph
- Retrieve detailed mechanism of action data from DrugBank (DG002)
- Obtain TFDA package insert warnings and contraindications (DG001), or source equivalent safety data from WHO/EMA given the drug's international availability
- If a predicted indication is identified, conduct indication-specific clinical trial and literature searches
- Evaluate whether Artemether's lack of Taiwan market presence necessitates an import/compassionate use pathway
Ansvarsfriskrivning
Detta innehåll är endast avsett för forskningsändamål och utgör inte medicinsk rådgivning. Klinisk validering krävs före klinisk tillämpning.